Symbols / AVXL $3.61 +3.14% Anavex Life Sciences Corp.

Healthcare • Biotechnology • United States • NMS
AVXL Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.

Fundamentals
Scroll to Statements
Market Cap 334.55M Enterprise Value 192.60M Income -39.95M Sales — Book/sh 1.37 Cash/sh 1.42
Dividend Yield — Payout 0.00% Employees 34 IPO — P/E — Forward P/E -25.79
PEG — P/S — P/B 2.64 P/C — EV/EBITDA — EV/Sales —
Quick Ratio 20.81 Current Ratio 20.87 Debt/Eq — LT Debt/Eq — EPS (ttm) -0.46 EPS next Y -0.14
EPS Growth — Revenue Growth — Earnings 2026-05-11 ROA -21.56% ROE -33.63% ROIC —
Gross Margin 0.00% Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 92.67M Shs Float 89.78M Short Float 21.64%
Short Ratio 9.66 Short Interest — 52W High 13.99 52W Low 2.61 Beta 1.18 Avg Volume 1.49M
Volume 752.34K Target Price $22.00 Recom None Prev Close $3.50 Price $3.61 Change 3.14%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$22.00
Mean price target
2. Current target
$3.61
Latest analyst target
3. DCF / Fair value
$-4.24
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.61
Low
$20.00
High
$24.00
Mean
$22.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-31 main D. Boral Capital Buy → Buy $24
2026-03-26 main D. Boral Capital Buy → Buy $24
2026-03-23 main D. Boral Capital Buy → Buy $24
2026-02-10 reit HC Wainwright & Co. Buy → Buy $20
2026-02-09 main D. Boral Capital Buy → Buy $24
2026-01-06 main D. Boral Capital Buy → Buy $24
2025-12-19 main D. Boral Capital Buy → Buy $24
2025-12-19 reit HC Wainwright & Co. Buy → Buy $20
2025-12-15 main D. Boral Capital Buy → Buy $24
2025-11-28 reit HC Wainwright & Co. Buy → Buy $20
2025-11-26 main D. Boral Capital Buy → Buy $24
2025-11-19 main HC Wainwright & Co. Buy → Buy $20
2025-11-14 main D. Boral Capital Buy → Buy $24
2025-10-29 main D. Boral Capital Buy → Buy $46
2025-10-24 down Jones Trading Buy → Hold —
2025-10-07 reit HC Wainwright & Co. Buy → Buy $42
2025-10-02 main D. Boral Capital Buy → Buy $46
2025-10-01 main D. Boral Capital Buy → Buy $46
2025-09-10 reit HC Wainwright & Co. Buy → Buy $42
2025-09-10 main D. Boral Capital Buy → Buy $46
News
RSS: Latest AVXL news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-09-11 MISSLING CHRISTOPHER U Chief Executive Officer — 187,500 $5.04 $945,000
2025-06-05 THOMAS STEFFEN PHD Director — 50,000 $1.76 $88,000
2025-03-24 MISSLING CHRISTOPHER U Chief Executive Officer — 500,000 $0.92 $460,000
2024-06-14 DONHAUSER PETER D.O. Director — 2,835 $3.64 $10,319
2024-05-15 THOMAS STEFFEN PHD Director — 5,000 $4.52 $22,600
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
51.37
-2.71%
52.80
-5.27%
55.74
+9.32%
50.99
Research And Development
37.59
-10.15%
41.84
-4.30%
43.72
+15.30%
37.92
Selling General And Administration
13.82
+25.16%
11.04
-8.36%
12.05
-7.83%
13.07
General And Administrative Expense
13.82
+25.16%
11.04
-8.36%
12.05
-7.83%
13.07
Other Gand A
13.82
+25.16%
11.04
-8.36%
12.05
-7.83%
13.07
Other Operating Expenses
-0.04
+50.67%
-0.07
-200.00%
-0.03
—
Total Expenses
51.37
-2.71%
52.80
-5.27%
55.74
+9.32%
50.99
Operating Income
-51.37
+2.71%
-52.80
+5.27%
-55.74
-9.32%
-50.99
Total Operating Income As Reported
-51.41
+2.78%
-52.88
+5.18%
-55.76
-9.37%
-50.99
EBITDA
-46.38
-7.85%
-43.00
+7.60%
-46.54
+2.27%
-47.62
Normalized EBITDA
-46.05
-6.61%
-43.19
+7.12%
-46.50
+0.46%
-46.72
EBIT
-46.38
-7.85%
-43.00
+7.60%
-46.54
+2.27%
-47.62
Total Unusual Items
-0.33
-275.66%
0.19
+572.50%
-0.04
+95.58%
-0.90
Total Unusual Items Excluding Goodwill
-0.33
-275.66%
0.19
+572.50%
-0.04
+95.58%
-0.90
Net Income
-46.38
-7.85%
-43.00
+9.48%
-47.51
+0.99%
-47.98
Pretax Income
-46.38
-7.85%
-43.00
+9.48%
-47.51
+0.24%
-47.62
Net Non Operating Interest Income Expense
4.68
-36.09%
7.32
+31.77%
5.55
+486.59%
0.95
Interest Expense Non Operating
0.00
0.00
-100.00%
0.96
0.00
Net Interest Income
4.68
-36.09%
7.32
+31.77%
5.55
+486.59%
0.95
Interest Expense
0.00
0.00
-100.00%
0.96
0.00
Interest Income Non Operating
4.68
-36.09%
7.32
+12.29%
6.52
+588.38%
0.95
Interest Income
4.68
-36.09%
7.32
+12.29%
6.52
+588.38%
0.95
Other Income Expense
0.32
-87.26%
2.48
-7.39%
2.68
+10.71%
2.42
Other Non Operating Income Expenses
0.65
-71.72%
2.29
-15.71%
2.72
-18.21%
3.32
Gain On Sale Of Security
-0.33
-275.66%
0.19
+572.50%
-0.04
+95.58%
-0.90
Tax Provision
—
0.00
-100.00%
0.01
-98.04%
0.36
Tax Rate For Calcs
0.00
0.00
0.00
-100.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
+100.00%
-0.19
Net Income Including Noncontrolling Interests
-46.38
-7.85%
-43.00
+9.48%
-47.51
+0.99%
-47.98
Net Income From Continuing Operation Net Minority Interest
-46.38
-7.85%
-43.00
+9.48%
-47.51
+0.99%
-47.98
Net Income From Continuing And Discontinued Operation
-46.38
-7.85%
-43.00
+9.48%
-47.51
+0.99%
-47.98
Net Income Continuous Operations
-46.38
-7.85%
-43.00
+9.48%
-47.51
+0.99%
-47.98
Normalized Income
-46.05
-6.61%
-43.19
+9.00%
-47.47
-0.43%
-47.26
Net Income Common Stockholders
-46.38
-7.85%
-43.00
+9.48%
-47.51
+0.99%
-47.98
Diluted EPS
-0.54
-3.85%
-0.52
+13.33%
-0.60
+3.23%
-0.62
Basic EPS
-0.54
-3.85%
-0.52
+13.33%
-0.60
+3.23%
-0.62
Basic Average Shares
85.29
+2.18%
83.47
+4.61%
79.79
+3.74%
76.91
Diluted Average Shares
85.29
+2.18%
83.47
+4.61%
79.79
+3.74%
76.91
Diluted NI Availto Com Stockholders
-46.38
-7.85%
-43.00
+9.48%
-47.51
+0.99%
-47.98
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Total Assets
103.81
-23.42%
135.57
-12.19%
154.39
+1.10%
152.71
Current Assets
103.81
-23.42%
135.57
-12.19%
154.39
+1.10%
152.71
Cash Cash Equivalents And Short Term Investments
102.58
-22.40%
132.19
-12.47%
151.02
+1.25%
149.16
Cash And Cash Equivalents
102.58
-22.40%
132.19
-12.47%
151.02
+1.25%
149.16
Receivables
0.81
-66.97%
2.45
-9.60%
2.71
-15.16%
3.19
Taxes Receivable
0.81
-66.97%
2.45
-9.60%
2.71
-15.16%
3.19
Prepaid Assets
—
—
—
0.35
Current Deferred Assets
—
—
—
—
Other Current Assets
0.43
-53.92%
0.93
+42.57%
0.65
+84.46%
0.35
Total Non Current Assets
0.00
0.00
0.00
0.00
Total Liabilities Net Minority Interest
8.95
-41.54%
15.30
+22.10%
12.53
+22.71%
10.21
Current Liabilities
8.95
-41.54%
15.30
+22.10%
12.53
+22.71%
10.21
Payables And Accrued Expenses
6.58
-49.14%
12.94
+26.11%
10.26
+21.07%
8.47
Payables
4.25
-55.86%
9.63
+122.74%
4.32
+12.99%
3.83
Accounts Payable
4.25
-55.86%
9.63
+122.74%
4.32
+12.99%
3.83
Current Accrued Expenses
2.33
-29.56%
3.31
-44.26%
5.93
+27.72%
4.65
Pensionand Other Post Retirement Benefit Plans Current
1.56
+2.29%
1.53
+12.28%
1.36
+4.78%
1.30
Current Deferred Liabilities
0.81
-4.39%
0.84
-8.18%
0.92
+106.53%
0.44
Current Deferred Revenue
0.81
-4.39%
0.84
-8.18%
0.92
+106.53%
0.44
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
0.00
Stockholders Equity
94.87
-21.12%
120.26
-15.22%
141.85
-0.45%
142.49
Common Stock Equity
94.87
-21.12%
120.26
-15.22%
141.85
-0.45%
142.49
Capital Stock
0.09
+2.35%
0.09
+3.66%
0.08
+5.13%
0.08
Common Stock
0.09
+2.35%
0.09
+3.66%
0.08
+5.13%
0.08
Preferred Stock
—
—
—
0.00
Share Issued
86.67
+2.21%
84.80
+3.33%
82.07
+5.29%
77.94
Ordinary Shares Number
86.67
+2.21%
84.80
+3.33%
82.07
+5.29%
77.94
Additional Paid In Capital
477.23
+4.60%
456.25
+4.92%
434.84
+12.08%
387.98
Retained Earnings
-382.45
-13.80%
-336.07
-14.67%
-293.07
-19.35%
-245.56
Total Equity Gross Minority Interest
94.87
-21.12%
120.26
-15.22%
141.85
-0.45%
142.49
Total Capitalization
94.87
-21.12%
120.26
-15.22%
141.85
-0.45%
142.49
Working Capital
94.87
-21.12%
120.26
-15.22%
141.85
-0.45%
142.49
Invested Capital
94.87
-21.12%
120.26
-15.22%
141.85
-0.45%
142.49
Net Tangible Assets
94.87
-21.12%
120.26
-15.22%
141.85
-0.45%
142.49
Tangible Book Value
94.87
-21.12%
120.26
-15.22%
141.85
-0.45%
142.49
Line Item Trend 2025-09-30 2024-09-30 2023-09-30 2022-09-30
Operating Cash Flow
-39.04
-26.72%
-30.81
-10.89%
-27.79
-14.63%
-24.24
Cash Flow From Continuing Operating Activities
-39.04
-26.72%
-30.81
-10.89%
-27.79
-14.63%
-24.24
Net Income From Continuing Operations
-46.38
-7.85%
-43.00
+9.48%
-47.51
+0.99%
-47.98
Other Non Cash Items
—
—
0.84
—
Stock Based Compensation
11.55
+22.37%
9.44
-42.35%
16.37
-10.93%
18.38
Change In Working Capital
-4.22
-253.20%
2.75
+9.86%
2.50
-53.27%
5.36
Change In Receivables
1.64
+530.77%
0.26
-46.28%
0.48
-91.86%
5.94
Change In Prepaid Assets
0.50
+280.58%
-0.28
+7.02%
-0.30
-30000.00%
0.00
Change In Payables And Accrued Expense
-6.32
-322.18%
2.85
+54.03%
1.85
+416.27%
-0.58
Change In Accrued Expense
-0.94
+61.67%
-2.46
-282.22%
1.35
+309.09%
0.33
Change In Payable
-5.38
-201.38%
5.30
+967.40%
0.50
+154.38%
-0.91
Change In Account Payable
-5.38
-201.38%
5.30
+967.40%
0.50
+154.38%
-0.91
Change In Other Working Capital
-0.04
+50.67%
-0.07
-115.86%
0.47
—
Financing Cash Flow
9.43
-21.22%
11.97
-59.61%
29.65
+39.29%
21.29
Cash Flow From Continuing Financing Activities
9.43
-21.22%
11.97
-59.61%
29.65
+39.29%
21.29
Net Common Stock Issuance
9.20
-18.49%
11.28
-59.52%
27.88
+32.83%
20.98
Proceeds From Stock Option Exercised
2.94
+325.90%
0.69
-61.09%
1.78
+75.84%
1.01
Net Other Financing Charges
—
—
—
-0.71
Changes In Cash
-29.61
-57.19%
-18.84
-1109.49%
1.87
+163.25%
-2.95
Beginning Cash Position
132.19
-12.47%
151.02
+1.25%
149.16
-1.94%
152.11
End Cash Position
102.58
-22.40%
132.19
-12.47%
151.02
+1.25%
149.16
Free Cash Flow
-39.04
-26.72%
-30.81
-10.89%
-27.79
-14.63%
-24.24
Income Tax Paid Supplemental Data
0.12
-58.33%
0.30
+120.59%
0.14
-58.41%
0.33
Common Stock Issuance
9.20
-18.49%
11.28
-59.52%
27.88
+32.83%
20.98
Issuance Of Capital Stock
9.20
-18.49%
11.28
-59.52%
27.88
+32.83%
20.98
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category